Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non–small-cell lung cancer: a phase 3 randomized clinical trial

J Wang, S Lu, X Yu, Y Hu, Y Sun, Z Wang… - JAMA …, 2021 - jamanetwork.com
… as first-line treatment for patients with advanced sq-NSCLC. … 3 clinical trial was conducted
at 46 sites in China between July 2018 and June 2019 and included patients with treatment-…

… for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

A Sezer, S Kilickap, M Gümüş, I Bondarenko… - The Lancet, 2021 - thelancet.com
… in clinical trials, making the present study more reflective of real-world clinical practice. …
of platinum-doublet chemotherapy in the first-line treatment of patients with advanced non-small-…

… with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized clinical trial

NA Rizvi, BC Cho, N Reinmuth, KH Lee, A Luft… - JAMA …, 2020 - jamanetwork.com
… chemotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer.
… 3 randomized clinical trial (MYSTIC) was conducted at 203 cancer treatment centers in 17 …

… or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial

K Shitara, E Van Cutsem, YJ Bang, C Fuchs… - JAMA …, 2020 - jamanetwork.com
… that reported in prior first-line global studies in patients with G… be necessary in future clinical
studies evaluating the delayed … for treatment with pembrolizumab in an earlier line of therapy

[HTML][HTML] A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of …

L Paz-Ares, D Vicente, A Tafreshi, A Robinson… - Journal of Thoracic …, 2020 - Elsevier
… To characterize the treatment effect of pembrolizumab on the next line of therapy, we …
objective tumor progression on next-line treatment or death, whichever occurred first. In addition, to …

… on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial

…, L Chen, L Bai, J Zhang, ESCORT-1st Investigators - Jama, 2021 - jamanetwork.com
… 2 and the current recommended standard first-line therapy for this advanced or metastatic
disease … clinical studies. Therefore, novel drugs and strategies are required to improve clinical

First-line immunotherapy for non–small-cell lung cancer

M Reck, J Remon, MD Hellmann - Journal of Clinical Oncology, 2022 - ascopubs.org
… Looking forward, there are several new agents being evaluated in randomized clinical
trials in the first line, which could soon be integrated into our clinical armamentarium. …

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular …

GK Abou-Alfa, SL Chan, M Kudo, G Lau, RK Kelley… - 2022 - ascopubs.org
… Conclusions: HIMALAYA was the first large phase 3 trial with a diverse, representative
uHCC … , novel, first-line standard of care systemic therapy for uHCC. Clinical trial information: …

Innate immunity: the first line of defense against SARS-CoV-2

MS Diamond, TD Kanneganti - Nature immunology, 2022 - nature.com
… , many treatment strategies have been investigated. The rate of clinical trials for COVID-19
has … Clinical trials of these treatments have led to FDA approval of remdesivir and EUA for the …

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

A Lamarca, DH Palmer, HS Wasan, PJ Ross… - The Lancet …, 2021 - thelancet.com
… benefits and risks from second-line FOLFOX chemotherapy in advanced biliary tract … line
treatment for advanced biliary tract cancer and the reference regimen for further clinical trials